Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635148 · ClinicalTrials.gov registry record · Phase 2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
A Phase 2 study of Geographic Atrophy and Macular Degeneration, sponsored by Janssen Research & Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
- 20
- Study locations
NCT06635148 is a Phase 2 study of Geographic Atrophy and Macular Degeneration that is actively recruiting participants, run by Janssen Research & Development. The registered enrollment target is 274 participants, above the 212-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (29% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06635148, a Phase 2 study of Geographic Atrophy and Macular Degeneration, is actively recruiting participants, sponsored by Janssen Research & Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
Conditions Studied
Interventions
- DRUG JNJ-81201887
- OTHER Sham Procedure
Study Locations (20)
California
- Retina Consultants of Orange County - Fullerton
- Shiley Eye Institute Jacobs Retina Center - La Jolla
- California Retina Consultants - Oxnard
- California Eye Medical Specialists - Pasadena
- Retina Consultants San Diego - Poway
- Bay Area Retina Associates - Walnut Creek
Florida
- Retina Group of Florida - Fort Lauderdale
- VitreoRetinal Associates, PA - Gainesville
- Retina Specialty Institute - Pensacola
- Retina Vitreous Associates of Florida - St. Petersburg
Maryland
- Retina Specialists - Baltimore
- The Retina Group of Washington - Chevy Chase
- Cumberland Valley Retina Consultants - Hagerstown
Georgia
- Georgia Retina - Marietta
- Marietta Eye Clinic - Marietta
Arizona
- Retina Associates Southwest PC - Tucson
Illinois
- University Retina - Lemont
Indiana
- Midwest Eye Institute - Carmel
Maine
- Maine Eye Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2030-07-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06635148
The ClinicalTrials.gov registry entry for NCT06635148 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 212-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (29% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which JNJ-81201887 is the first listed.
NCT06635148 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Maryland.
Frequently Asked Questions
What is clinical trial NCT06635148 about?
NCT06635148 is a clinical study titled "A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)". The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
What is the current status of trial NCT06635148?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2024-09-19. Estimated completion is 2030-07-16.
What conditions does trial NCT06635148 study?
This clinical trial studies the following conditions: Geographic Atrophy, Macular Degeneration.
What interventions are being tested in trial NCT06635148?
The interventions under investigation include: JNJ-81201887 (DRUG), Sham Procedure (OTHER).
Who is sponsoring clinical trial NCT06635148?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635148 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.